U.S. markets close in 5 hours 11 minutes
  • S&P 500

    4,127.97
    -12.09 (-0.29%)
     
  • Dow 30

    32,809.26
    -23.28 (-0.07%)
     
  • Nasdaq

    12,508.99
    -135.47 (-1.07%)
     
  • Russell 2000

    1,920.31
    -20.90 (-1.08%)
     
  • Crude Oil

    91.70
    +0.94 (+1.04%)
     
  • Gold

    1,810.80
    +5.60 (+0.31%)
     
  • Silver

    20.47
    -0.15 (-0.72%)
     
  • EUR/USD

    1.0229
    +0.0034 (+0.34%)
     
  • 10-Yr Bond

    2.8010
    +0.0360 (+1.30%)
     
  • GBP/USD

    1.2114
    +0.0032 (+0.27%)
     
  • USD/JPY

    134.9540
    -0.0190 (-0.01%)
     
  • BTC-USD

    23,077.23
    -1,090.28 (-4.51%)
     
  • CMC Crypto 200

    535.48
    -21.87 (-3.92%)
     
  • FTSE 100

    7,494.84
    +12.47 (+0.17%)
     
  • Nikkei 225

    27,999.96
    -249.28 (-0.88%)
     

GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.

The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets and tablets for oral suspension, the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com